NextCell Pharma's stem cell study in Type 1 Diabetes gets green light from the Medical Products Agency

NextCell Pharma AB ("NextCell") today announces that the Swedish Medical Products Agency has granted permission to conduct the clinical trial investigating the drug candidate ProTrans.

For more information regarding the clinical trial, please see press release from 15th of September.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the above contact person for publication on October 17th, 2017.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Phone: 0702-615 504

E-mail: mathias.svahn@nextcellpharma.com

www.nextcellpharma.com

About NextCell Pharma AB:

Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans™, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans™ consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.

Subscribe

Documents & Links